Impact of the Implementation of a Telemedicine Program on Patients Diagnosed with Asthma

Launched by HOSPITAL UNIVERSITARI DE BELLVITGE · Nov 2, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating how a mobile application called ESTOI can help patients with asthma better manage their condition. Asthma is a common respiratory disease, and many patients struggle to keep their symptoms under control. The trial aims to see if using this app can improve patients' treatment adherence, which means sticking to their prescribed medications, as well as enhance their overall quality of life and control of asthma symptoms. The study will last for a year and will include 108 patients who are receiving care at a specialized hospital in Spain. Participants will be divided into two groups: one will receive standard care, while the other will have additional support through the app.

To be eligible for this trial, participants must be at least 18 years old, diagnosed with asthma, and able to provide informed consent. They should not have received prior asthma education, and they need to be comfortable using a smartphone or tablet, as the app is essential for the study. Participants can expect regular monitoring of their asthma control, medication adherence, and quality of life through various questionnaires and tests. This trial is currently recruiting and aims to help improve the way asthma is managed using technology.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years with a diagnosis of asthma based on GEMA 5.2 2022.
• • Patients seen in the pulmonology service of the center.
• • Patients who have not previously received asthma education.
• • Capable of giving signed informed consent.
• Exclusion Criteria:
• • Patient who does not have a mobile device with Android or IOS system.
• • Lack of minimum technological knowledge for the use of the application (ESTOI).
• • People who are participating or have participated in a clinical trial in the last 6 months.
• • Patients diagnosed with other respiratory diseases except for obstructive sleep apnea (OSA), Asthma-COPD overlap syndrome (ACOS).
• • Patients with palliative or severe chronic illnesses that limit their life expectancy.